| Christopher W Valentine, MD | |
|
929 Jasonway Ave, Columbus, OH 43214-2464 | |
| (614) 538-2250 | |
| (614) 538-2256 |
| Full Name | Christopher W Valentine |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 26 Years |
| Location | 929 Jasonway Ave, Columbus, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336156660 | NPI | - | NPPES |
| 2380838 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 35080086 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Davita - Dublin | Dublin, OH | Dialysis facility |
| Davita - Meadowhawk Dialysis | Marysville, OH | Dialysis facility |
| Memorial Hospital | Marysville, OH | Hospital |
| Dublin Methodist Hospital | Dublin, OH | Hospital |
| Riverside Methodist Hospital | Columbus, OH | Hospital |
| Hardin Memorial Hospital | Kenton, OH | Hospital |
| Ohio State University State Health System | Columbus, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Riverside Nephrology Associates Inc | 8022058585 | 18 |
News Archive
Aegerion Pharmaceuticals, Inc. today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions.
Adult stem cells collected directly from human fat are more stable than other cells - such as fibroblasts from the skin - and have the potential for use in anti-aging treatments, according to researchers from the Perelman School of Medicine at the University of Pennsylvania.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011. Excluding the charge related to the United States Department of Justice investigations described below, and a charge of $50.0 million, or $0.17 per share net of tax, for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $0.95 per share.
Geneticists have long awaited the ability to simply knock out or add a single gene here and there, as desired, with accuracy and efficiency, and then study the exact consequences caused by the loss or addition of that genetic information.
› Verified 5 days ago
| Entity Name | Riverside Nephrology Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780676585 PECOS PAC ID: 8022058585 Enrollment ID: O20050504000951 |
News Archive
Aegerion Pharmaceuticals, Inc. today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions.
Adult stem cells collected directly from human fat are more stable than other cells - such as fibroblasts from the skin - and have the potential for use in anti-aging treatments, according to researchers from the Perelman School of Medicine at the University of Pennsylvania.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011. Excluding the charge related to the United States Department of Justice investigations described below, and a charge of $50.0 million, or $0.17 per share net of tax, for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $0.95 per share.
Geneticists have long awaited the ability to simply knock out or add a single gene here and there, as desired, with accuracy and efficiency, and then study the exact consequences caused by the loss or addition of that genetic information.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher W Valentine, MD 929 Jasonway Ave, Columbus, OH 43214-2464 Ph: (614) 538-2250 | Christopher W Valentine, MD 929 Jasonway Ave, Columbus, OH 43214-2464 Ph: (614) 538-2250 |
News Archive
Aegerion Pharmaceuticals, Inc. today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions.
Adult stem cells collected directly from human fat are more stable than other cells - such as fibroblasts from the skin - and have the potential for use in anti-aging treatments, according to researchers from the Perelman School of Medicine at the University of Pennsylvania.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011. Excluding the charge related to the United States Department of Justice investigations described below, and a charge of $50.0 million, or $0.17 per share net of tax, for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $0.95 per share.
Geneticists have long awaited the ability to simply knock out or add a single gene here and there, as desired, with accuracy and efficiency, and then study the exact consequences caused by the loss or addition of that genetic information.
› Verified 5 days ago
Sethu M. Madhavan, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 300 W 10th Ave, Columbus, OH 43210 Phone: 614-293-3387 Fax: 614-366-0073 | |
Amrik Singh Khalsa, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 700 Childrens Dr, Columbus, OH 43205 Phone: 614-722-2000 Fax: 614-722-4966 | |
Samuel Y. Han, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 410 W 10th Ave, Columbus, OH 43210 Phone: 614-293-6255 Fax: 614-293-1456 | |
Dr. Ruchi Bhatia, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3400 Olentangy River Rd, Columbus, OH 43202 Phone: 614-754-5500 Fax: 614-457-9519 | |
Adam T. Ramey, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 410 W 10th Ave, Columbus, OH 43210 Phone: 614-293-7499 Fax: 614-366-2360 | |
Albert J. Cook, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 460 W 10th Ave, Columbus, OH 43210 Phone: 614-293-2957 Fax: 614-685-6533 | |
Walter G. Hanel Iv, MD, PHD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 460 W 10th Ave, Columbus, OH 43210 Phone: 614-293-3196 Fax: 614-293-4812 |